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Abstract
Objective: A novel multi-drug resistance gene named as HA117 has been screened and cloned in
multidrug resisitant leukemia cell lines in our previous research, but its function is still unknown. In
this study, HA117 gene was investigated whether it could increase the drug resistance in chronic
myelogenous myeloid leukemia cell line K562.
Methods: HA117 was cloned and adenovirus vectors were constructed with the HA117 gene
(Adeasy-HA117). K562 cells were infected by Ad-HA117 to get the K562/Ad-HA117 cells with
HA117 gene expression. The infection efficiency and the multiplicity of infection (MOI) were
detected by fluorescence and flow cytometry. The expression of HA117 gene was detected by RT-
PCR. The drug sensitivities of K562/Ad-HA117 cells were detected by Methyl Thiazolyl
Tetrazolium (MTT) assay.
Results: Recombinant adenovirus vectors were constructed and a MOI of 100 is most suitable to
infect K562 cells. The infected K562 cells demonstrated in vitro production of HA117 mRNA as
measured by reverse-transcriptase polymerase chain reaction. There were no significant changes
in K562/Ad-HA117 cells growth, while the drug sensitivities of K562/Ad-HA117 cells to Vincristine,
Adriamycin, Etoposide, Daunorubicin, Mitomycin and Cyclophosphamide decreased 4.44, 7.18,
3.01, 9.53, 3.48 and 3.61 times than that of uninfected K562 cells, respectively (P < 0.05).
Conclusion: Expression of the novel gene HA117 could significantly increased the multi-drug
resistance of K562 cells, which indicated that HA117 is a functionally relevant multidrug resistance
gene.
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Introduction
Multi-drug resistance (MDR) of tumor cells, including
leukemia cells, is a defense mechanism for retaining
homeostasis when they are damaged by cytotoxic drugs
[1]. Tumor cells emerge a series of biological changes dur-
ing the development of MDR in them. In molecular mech-
anism, occurrence of tumor cells' MDR is because of
expression of genes related drug resistance [2]. To investi-
gate which genes were in regulation in MDR of tumor
cells, we established the multi-drug resistance cells HL-60/
MDR using acute myelocytic leukemia cell line HL-60 at
previous study. Then we screened and cloned the MDR
related genes in HL-60/MDR cells using differential
hybridization and gene chip [3,4] and found a novel gene
HA117 (GeneBank: AY230154) which may be related to
MDR[5]. In this study, adenovirus vectors were con-
structed with the HA117 gene (Adeasy-HA117) to investi-
gate whether HA117 gene could increase the drug
resistance in chronic myelogenous myeloid leukemia cell
line K562.
Methods
Reagents
Restriction enzymes and T4 ligases were bought from New
England Biolabs company, USA. DNA polymerase,
TaKaRa MiniBEST Plasmid Purification Kits, Agarose Gel
DNA Fragment Recovery Kits, RNAiso reagents, Reverse
Transcription PCR kits and primers were products of
TaKaRa Biotechnology (Dalian, China) CO., LTD. Lipo-
fectamine was from Invitrogen company, USA. The High-
quality fetal bovine serum and 1640 medium were prod-
ucts of Gibco Company, USA. Vincristine (VCR) was
offered by HuaLian Limited Company, ShangHai, China.
Adriamycin (ADM) was produced by AIBAO pharmaceu-
tical factory, Italy. Mitomycin was bought from Sigma
Company, USA. Etoposide was offerd by LianYunGang
pharmaceutical factory, China. Cytoxan was bought from
SuHeng pharmaceuticalfactory, JangSu, China. Daunoru-
bicin (DNR) was from Pharmacia Company, Italy.
Plasmids and cell lines
BJ5183 strain, shuttle plasmid pAdTraek-CMV with Green
Fluorescent Protein (GFP), adenoviral genome plasmid
pAdeasy-1 and 293 cells were given by professor Tong-
Chuan He in the molecular Oncology Laboratory of Chi-
cago University, USA. The plasmid PUC57-HA117 con-
taining HA117 gene, E. coli DH5α, and K562 cells were
stored in our laboratory.
Construction of recombined adenovirus Ad5-HA117[6]
Adenoviral shuttle plasmid pAdTrack-CMV and PUC57-
HA117 were incised by restriction enzyme HindIII and
KpnI. After incised, HA117 gene and pAdTrack-CMV were
recovered using Agarose Gel DNA Fragment Recovery Kit,
then linked by T4 joinase and transduced into E. coli
DH5α. The transformed positive clone pAdTrack-HA117
was selected and identified by incision enzyme and
sequence analysis. The pAdTrack-HA117 DNA was made
to be inlinearization by PmeI cutting and transformed
into adenoviral homologous shuttle plasmid BJ-Adeasy in
a CaCl2 precipitational way. Positive clones BJ-Adeasy-
HA117 were selected and transformed into competent cell
DH5α. Then Adeasy-HA117 was verified by Pac1 digest-
ing and packaged to be complete recombined adenovirus
Ad5-HA117 in 293 cells. The first generation 293 cells
were harvested and freezing-dissolved with solid carbon
dioxide three times when they were floating after trans-
fected 10–14 days. Supernatant containing virus was col-
lected and infected 293 cells to amplify the recombined
adenovirus massively. After amplified three turns and
purified with density gradient centrifugation, high titer
recombined adenovirus Ad5-HA117 was harvested and
stored in -80°C to be used.
The generation of recombinated adenovirus pAdeasy-HA117 Figure 2
The generation of recombinated adenovirus 
pAdeasy-HA117.
  
1d ×100               7 d ×100               1 4 d ×100 
Gel screening of Adeasy-HA117 after digested by Pac I Figure 1
Gel screening of Adeasy-HA117 after digested by Pac 
I. After digeted with Pac I, Adeasy-HA117 produced 4.5 kb 
DNA strap, which proved that the homologous recombina-
tion was successful. M: DNA Marker; 1,2: Adeasy-HA117
M     1       2  
9.4kb 
6.5kb 
4.3kb 
23kb  30kb
3.4kb
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Ad5-HA117 infected K562 cells in vitro
Human leukemic cells K562 were cultured were cultured
in 37°C in RPMI 1640 cell culture medium containning
10% fetal calf serum. The cells in logarithmic phase were
divided into 3 groups. The cells infected by Ad-HA117
were designed as experimental group and labeled as
K562/Ad-HA117. The cells infected by empty ecombined
adenovirus were control group and labeled as K562/Ad-
null. The cells uninfected were designed as blank control
group and labeled as K562. After cultured for 16 hours,
cells concentration was modulated to be 2.0 × 105/L with
1640 medium conaining 10% fetal bovine serum. Experi-
mental groups were set up according to different multi-
plicity of infection (MOI). MOIs of each groups were 1,
10, 50, 100, 500 and 1000. Every group set up 6 pores.
The efficiency of infection was detected using fluorescence
microscope at 24 hours after infection.
Reverse transcriptase-polymerase chain reaction (RT-
PCR) for HA117 gene in K562 cells
Total cellular RNA was isolated from k562/Ad-HA117
cells, K562/Ad-null cells and K562 cells using RNAiso rea-
gents at 24 hours after infection, respectively. The RT-PCR
reactions were carried out using Reverse Transcription
PCR kit. The upstream primer of β-actin was 5'-CTTTGG-
TATCGTGGAAGGACTC-3', and the downstream primer
was 5'-AGTGGGTGTCGCTGTTGAAGT-3'. The upstream
primer of HA117 gene was 5'-CAGAGTCAGGGACT-
TCAGCCTTAT-3', and the he downstream primer was 5'-
CTGTTTCCTTCTCACTCCCAACCA-3'. The PCR was per-
formed with a fist denaturation step at 94°C 5 minutes
and 35 cycles of denaturation at 94°C for 1 minute,
annealing at 68°C for 30 seconds and at 72°C for one
minute. The PCR reaction products were detected with gel
electrophoresis and ultraviolet transillumination.
MTT assays for drug sensitivity
The drug sensitivity of experimental cells to 5-fluorouracil
was determined by MTT assay at 24 hours after infection.
Cell suspension was collected into 96-well flat-bottomed
microtitre plates (1 × 105 cells/well). 6 concentrations of
5-fluorouracil were chosen according to preliminary
experiment and were added to wells of culture plate con-
taining 200 μl cell suspension. After cultured at 37°C for
24 hours, 50 μl of MTT solution (5.0 mg ml-1) were added
to each well and incubated for 4 hours. Then the mixture
containing the medium, drug, and unconverted MTT was
removed carefully. DMSO was added to each well to dis-
solve the formazan and absorbance was read at 450 nm
using a spectrophotometric microplate reader (SunRise,
Austria). The survival rate of tumor cells for each concen-
trations was calculated following the formula: survival
rate (%) = (1- ODdrug/ODcontrol) × 100. The 50% inhib-
iting concentration (IC50) of chemotherapeutic drugs was
calculated according to the suvival rate for each concentra-
tion. The drug-resistant factor (RF), also named drug-
Table 1: The rates of infection and survival of cell during different MOI
MOI
1 10 50 100 500 1000
Infection rates 0.47 ± 0.04 5.83 ± 0.07 10.65 ± 0.11 16.19 ± 0.31 20.27 ± 0.52 30.42 ± 2.31
Survivil rates 90.33 ± 1.21 85.27 ± 1.37 82.11 ± 1.63 81 ± 1.42 62.23 ± 2.15 40.25 ± 2.13
Fluorescent expression of K562 cells after transfected 24  hours Figure 3
Fluorescent expression of K562 cells after trans-
fected 24 hours. A:K562 cells; B: K562/Ad-HA117 cells 
expressed green fluorescence.
A˄×100᧥                     B ˄×100᧥
The infection rates of K562 cells during different MOI  detected by FCM Figure 4
The infection rates of K562 cells during different MOI 
detected by FCM. The infection rates were about 
39.72%~64.3%. A: MOI = 100; B: MOI = 1000.Journal of Experimental & Clinical Cancer Research 2009, 28:63 http://www.jeccr.com/content/28/1/63
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resistant index, was calculated with the following for-
mula: RF = experimental cells'IC50/control cells'IC50 [7].
All experiments were performed in triplicate.
Drug Elimination Experiments
Cells (2.0 × 106/L) in each group were incubated with
Daunomycin (7.5 μg/L) for 30 min and observed under a
fluorescence microscope. Then, cells were centrifugated
and the supernate were used to determine the concentra-
tions of daunomycin by flow cytometry.
Statistical Analysis
The results were given as mean ± standard deviation. Dif-
ferences in means of normally distributed data were
assessed by Student's t test with Bonferroni correction. P
value less than 0.05 is considered significant.
Results
Results of recombined adenovirus Ad5-HA117 
construction
By digested with HindIII and KpnI, a piece of 1.1 kb nucle-
otides (HA117 gene) was obtained and sequenced, which
indicated that the recombined plasimid pAdTrack/HA117
was constructed successfully. The pAdTrack-HA117 was
homologous recombined with BJ-Adeasy in E. coli. Then,
the recombined Adeasy-HA117 plasmid was identified by
Pac1 cutting. One 30 kb strap and one 4.5 kb strap could
be seen by agarose gel electrophoresis, which proved that
the homologous recombination was successful (Figure 1).
Then, pAdeasy-HA117 was transfected into 293 cells.
After two weeks, the transfected 293 cells became to be
float from adherence observed by the GFP fluorescence
intensity (Figure 2). At this time, the completed recom-
bined adenovirus Ad5-HA117 was harvested.
Expression of fluorescence and most suitable adenovirus 
amount of infetected K562 cells
The K562 cells had green fluorescent expression at 24
hours after infected (Figure 3). It was found that the infec-
tion rate of adenovirus to K562 cells increased with the
adenovirus amout increased. Both cells' survival rate
(exceeded 80%) and infection rate (reached 39.72%)
were fairly well when MOI was 100. And the weak and
dead cells increased obviously when MOI exceeded 100.
So MOI 100 was chosen as the most suitable amount for
the further investigation (Table 1 and Figure 4).
RT-PCR results for HA117 gene expression in k562 cells
Both uninfected K562 cells and K562/Ad-null cells had no
HA117 gene expression, and HA117 expressed only in the
K562/Ad-HA117 cells, which indicated that K562 cells
could express exogenous HA117 gene when infected by
Ad-HA117 (figure 5).
The MTT assays results for K562 cells' drug sensitivity
The survival rates of K562/HA117 cells increased than that
of K562 cells and K562/Ad-null cells. The RFs of K562/Ad-
HA117 cells to VCR, ADM, Vp-16, DNR, MMC and CTX
were 4.44, 7.18, 3.01, 9.53, 3.48 and 3.61 times than that
of uninfected K562 cells, respectively (P < 0.05). And
there was no significantly difference in RFs between the
uninfected K562 cells and K562/Ad-null cells. It demon-
strated that exogenous HA117 gene could induce K562
Fluorescence intensity of DNR in K562 cells Figure 6
Fluorescence intensity of DNR in K562 cells. A: K562 
cells, B: K562/Ad cells, C: K562/Ad-HA117 cells.
The expression of HA117 gene mRNA in K562 cells Figure 5
The expression of HA117 gene mRNA in K562 cells. 
M: DNA marker; 1:K562 cells; 2: K562/Ad-null cells had no 
HA117 gene expression; 3:K562/Ad-HA117 cells had HA117 
gene expression. The DNA strap having 397 bp was β-actin.
M      1       2       3
1500bp 
500bp 
400bp 
397bp 
300bp 
200bp 
119bp 
100bp 
Table 2: The drug senstivity experimental results of K562 cells
Drugs inhibitory concentration(IC50)
K562 *K562/Ad-HA117 *K562/Ad-null
VCR 0.052 ± 0.009 0.810 ± 0.060 0.031 ± 0.010
ADM 0.203 ± 0.018 0.985 ± 0.12 0.210 ± 0.014
VP-16 3.221 ± 0.021 7.834 ± 0.002 3.132 ± 0.031
DNR 0.089 ± 0.025 0.654 ± 0.203 0.091 ± 0.013
MMC 3.421 ± 0.215 11.023 ± 0.542 3.203 ± 0.189
CTX 1.654 ± 0.104 5.003 ± 0.006 1.721 ± 0.056
notice: *P < 0.05, compared with K562 and K562/Ad-null.Journal of Experimental & Clinical Cancer Research 2009, 28:63 http://www.jeccr.com/content/28/1/63
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cells to develop drug resistance to the chemotherapeutic
drugs (Table 2).
HA117 gene was no drug-excretion function
Daunorubicin was one kind of anti-cancer drugs which
had autofluorescence. The drug's concentration in the
cells could be determined directly by fluorescence inten-
sity with a fluorescent microscope. There was no signifi-
cant difference in the fluorescence intensity between the
experimental group and control group, which indicated
that HA117 gene had no drug-excretion function (Figure
6).
Discussion
All-trans retinoic acid (ATRA) has been proposed as an
alternative therapy for acute promyelocytic leukemia
(APL), which is a specific subtype of acute myeloid leuke-
mia (AML) (AML, M3) characterized by a chromosomal
translocation t (15; 17) involving the promyelocytic
leukemia (PML) gene on chromosome 15 and the retinoic
acid receptor-alpha (RARa) gene on chromosome 17,
Since 1988[8,9], we and others have shown that a high
proportion of APL patients achieve complete remission
(CR) with ATRA alone[10,11]. Unfortunately, further clin-
ical experience has shown that they do not remain in
long-term remissions if maintained on ATRA therapy
alone [12]. When relapse occurs shortly after ATRA with-
drawal in APL, the ATRA fails to induce a second remis-
sion and the APL cells develop drug resistance to other
chemotherapeutics[13]. The exact mechanism is still
unknown and there are some putative mechanisms for
this phenomenon involving in overexpression of MN1
[14], mutations of RARa as noted in HL-60 cells[15],
selection of non-APL leukemia clones and increased
expression of proteins involved in ATRA's metabo-
lism[16,17]. In our previous researches, we have estab-
lished the suppressive subtractive hybridization library of
the multi-drug resistance cell line HL-60/MDR inducing
by ATRA to investigate the mechanism of MDR in APL
cells. 12 MDR related genes with significant differential
expression have been screened out to homology analysis.
Of these, 11 matched known genes and the rest one
showed no significant homology to human or non-
human known sequences. It was named as gene clone
HA117, but its function is unkown.
As we know, the recombined adenovirus vector is one of
the vectors most commonly used for gene therapy. Com-
pared to other viral vectors, it offer many advantages
including relatively low pathogenicity in humans, wide
host range and high replication efficiency[18,19]. There-
fore, we selected the improved plasimid pAdeasy to con-
struct the recombined adenovirus Ad-HA117 containing
HA117 gene and K562 cells were infected by Ad-HA117 to
get the K562/Ad-HA117 cells with HA117 gene expres-
sion. The infection efficiency and the multiplicity of infec-
tion (MOI) were detected by fluorescence and flow
cytometry, it was found that the infection rate of adenovi-
rus to K562 cells increased with the adenovirus amout
increased and the weak and dead cells increased obviously
when MOI exceeded 100. So MOI 100 was chosen as the
most suitable amount for the further researches (Table 1
and Figure 4). We also found that HA117 expressed only
in the K562/Ad-HA117 cells and exogenous HA117 gene
could induce K562 cells to develop drug resistance to the
chemotherapeutic drugs such as adriamycin, vinblastine,
mitoxantrone and etoposide. But HA117 gene had no
drug-excretion function
In conclusion, we constructed the recombined adenovirus
Ad-HA117 which could express the novel gene HA117
and its expression could significantly increased the multi-
drug resistance of K562 cells. It indicated that HA117 is a
functionally relevant multidrug resistance gene. But
whether HA117 could increase the drug resistance of
tumor cell in vivo needs further study.
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